Researchers agree that early detection is the key to optimising the potential success of drug and device therapies – and that these therapies would work most effectively if they were admini
Increasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role in clinical trials and the potential impact of expanded use.
With the 12th annual Rare Disease Day on the horizon, it’s a pertinent time to think about how one of the most exciting technological innovations of the last decade, artificial intelligence
As Rare Disease day 2020 approaches, we take a look at the biggest challenges facing orphan drug developers and ask whether the future is bright or bleak for these difficult conditions.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.